To evaluate whether an observed TMT effect is due to the combination of CCNU and temozolomide treatment or due to MGMT promoter methylation per se, which is the most important prognostically relevant marker in glioblastoma, it was important to exclusively include MGMT promoter methylated patients in both cohorts—CeTeG as well as Stupp. This evidence concerns the gene CCNO and glioblastoma.